Palonosetron Fresenius Kabi (Palonosetron Hydrochloride)

Palonosetron Hydrochloride, the active ingredient in Palonoset2, is a selective 5‑HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It is used to prevent nausea and vomiting associated with chemotherapy and postoperative settings in adult patients. GNH USA supplies Palonoset2 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Palonoset2 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Palonosetron is a 5‑HT3 receptor antagonist indicated for the prevention of nausea and vomiting in several clinical contexts.

- Chemotherapy‑induced nausea and vomiting (CINV): Provides long‑lasting protection against acute and delayed episodes following highly emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): Reduces the incidence of nausea and vomiting after general anesthesia. - Radiotherapy‑induced nausea and vomiting: Helps control nausea associated with radiation treatment of the abdomen or pelvis. - Anticipatory nausea and vomiting: Used in patients who have previously experienced CINV or PONV to prevent recurrence. - Adjunct therapy in combination regimens: Integrated into multi‑drug anti‑emetic protocols for enhanced efficacy.

Palonosetron is generally well tolerated, but adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: transient gastrointestinal slowing. - Fatigue: feeling of tiredness without other cause. - Diarrhoea: occasional loose stools. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe hypersensitivity: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Severe constipation or intestinal obstruction. - Pulmonary edema: fluid accumulation in the lungs. - Neuro‑muscular weakness: rare neuromuscular complications.

When using Palonosetron, clinicians should consider several safety aspects.

- Cardiac monitoring: assess baseline ECG in patients with known QT prolongation risk. - Concomitant serotonergic drugs: evaluate for additive serotonin effects. - Electrolyte disturbances: correct hypokalaemia, hypomagnesemia, or hypocalcaemia before administration. - Renal or hepatic impairment: adjust monitoring in patients with severe organ dysfunction. - Pregnancy and lactation: use only if the potential benefit outweighs risk. - Store at ambient temperature: keep in original packaging, protect from light and moisture.

Palonosetron may interact with other medications, requiring attention to the level of risk.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: concurrent use can increase toxicity without added benefit. - QT‑prolonging agents: combined use may heighten risk of cardiac arrhythmias. - Strong CYP3A4 inhibitors: may raise palonosetron plasma concentrations.

Moderate Interactions (Monitor Closely): - Serotonergic antidepressants (SSRIs, SNRIs): monitor for signs of serotonin syndrome. - Anticholinergic drugs: may exacerbate constipation. - Diuretics: watch for electrolyte shifts that could affect cardiac repolarisation. - Antifungal azoles: potential modest increase in exposure. - Opioid analgesics: observe for additive nausea risk.